Table 3.

Combined assessment of infliximab and anti-infliximab for responders receiving infliximab

Imaeda et al 27	ADAbs+	ADAbs−	Total	Population and anti-TNFα therapy; tests
Anti-TNFα−	LOR=9	LOR=0	LOR=9	Responders on infliximab maintenance; ELISA. Prevalence of LOR=29.3%
	RESP=1	RESP=7	RESP=8
Anti-TNFα+	LOR=3	LOR=5	LOR=8
	RESP=3	RESP=30	RESP=33
Total	LOR=12	LOR=5	LOR=17
	RESP=4	RESP=37	RESP=41

The probability of a patient returning each of the four possible test result combinations was:

ADAbs+/anti-TNFα−, 0.172; ADAbs+/anti-TNFα+, 0.103; ADAbs−/anti-TNFα−, 0.121; ADAbs−/anti-TNFα+, 0.603.

The probabilities of losing response according to the category of test result were 0.900, 0.500, 0.000 and 0.143, respectively.

ADAbs, antidrug antibodies; LOR, loss of response; RESP, responders; TNF, tumour necrosis factor.